Verona commences Phase IIa trial of RPL554 to treat CF

UK-based biopharmaceutical company Verona Pharma has commenced the enrolment and dosing of patients in a Phase IIa clinical trial of RPL554 for the treatment of cystic fibrosis (CF).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news